Glaxo’s $3.1bn tax hit could be blessing in disguise

Breakingviews is a subscription service which provides its readers with unique agenda-setting financial insight on the major financial stories 24 hours a day, as they break across the globe. And so keeps them better informed.

Our columnists crunch the numbers, think through the ramifications of events and deliver innovative and hard-hitting perspectives. We produce concise articles that take only a couple of minutes to read, get straight to the point and express a clear view.

Read one of our recent articles

Donald Trump’s boomerang will hit the US hard

Email a friend

Plese complete the form below.

13 Sep 2006 | By   Robert Cyran Follow @rob_cyran
share

Now that the drugs giant knows the size of its settlement, it can and should concentrate on firming its flabby balance sheet. If it wants to buy BristolMyers it should pay more cash than paper. Or it could take on £17bn of debt for a megapayout to shareholders.

This Content is for
Subscribers only

Sign In

or

Request a Free Trial

Thomson Reuters Products

Westlaw

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.

Onesource

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.

Checkpoint

The industry leader for online information for tax, accounting and finance professionals.


LSEG Products

Workspace

Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.

Data Catalogue

Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.

World-Check

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.


© Reuters News & Media Ltd 2025. All rights reserved.

This website uses cookies to ensure you get the best experience on our website.  Learn more